- Many drugs commonly used by patients with chronic kidney disease (CKD) contain phosphorus, contributing to the intestinal load.
Why this matters
- Medication-related phosphorus load is estimated to be
- The authors cite a "lack of transparency" from pharmaceutical companies, which place phosphorus as an excipient on the label but neglect to specify the exact quantity.
- Phosphate levels in specific drugs varies by formulation (including branded vs generic) and manufacturer (e.g., amlodipine 10 mg: 7.9-165.6 mg; paroxetine 20 mg: 55.8-295.8 mg).
- Over 20% of formulations for drugs in these categories contains phosphorus as an excipient:
- Calcium channel blockers: 51%,
- Pain medications: 44.8%,
- Antipsychotics: 35.1%,
- Vitamins: 29%,
- Diabetes medications: 23.8%,
- Beta blockers: 23%, and
- Cholesterol-lowering therapy: 21%.
- The most common form of excipient phosphorus was calcium hydrogen phosphate, which has lower bioavailability (70%-90%) than sodium hydrogen phosphate (100%), but remains a concern in CKD.
- Review highlighting the phosphorus content in medications prescribed to patients with CKD.
- Funding: Bayer, National Natural Science Foundation of China, State Key Research Development Programme of China.
- Incomplete manufacturer data.